AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34798038 — intervention group
Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 397
Study 33358809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair housing (PR; 2 hutches with common outdoor space)
Number of subjects: 24
Study 33358809 — intervention group
Group type: COMPARATOR
Intervention: Individual housing (INDV; 1 hutch plus outdoor space)
Number of subjects: 24
Study 33358809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pair housing (PR)
Number of subjects: 24
Study 32366785 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐florbetapir PET
Number of subjects: 57
Study 32366785 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐FDG PET
Number of subjects: 57
Study 34289782 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Display B with 100% frequency (100B)
Number of subjects: 18
Study 34289782 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Display A with 50% frequency (50A)
Number of subjects: 18
Study 34289782 — intervention group
Group type: COMPARATOR
Intervention: No feedback (0FB)
Number of subjects: 18
Study 33899093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 245
Study 33899093 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 245
Study 33899093 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol/Dronedarone
Number of subjects: 245
Study 33899093 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I/III AADs (overall)
Number of subjects: 245
Study 33899093 — intervention group
Group type: COMPARATOR
Intervention: Control group (targeted therapy)
Number of subjects: 245
Study 33683586 — intervention group
Group type: EXPERIMENTAL
Intervention: Substrate with organic compost (S1) at 50% effluent dose
Number of subjects: 0
Study 33683586 — intervention group
Group type: EXPERIMENTAL
Intervention: Substrate with water hyacinth fibers (S2)
Number of subjects: 0
Study 33683586 — intervention group
Group type: EXPERIMENTAL
Intervention: Substrate with organic compost (S1)
Number of subjects: 0
Study 33683586 — intervention group
Group type: COMPARATOR
Intervention: Control treatment at doses 25% and 50% in S1
Number of subjects: 0
Study 33683586 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 0
Study 32585700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 949
Study 32585700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 949
Study 32585700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 33826913 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide
Number of subjects: 0
Study 33826913 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 32164679 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouldering psychotherapy (BPT)
Number of subjects: 133
Study 32164679 — intervention group
Group type: COMPARATOR
Intervention: Home-based supervised exercise programme (EP)
Number of subjects: 133
Study 32283762 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (180 mg/day for 12 weeks)
Number of subjects: 0
Study 34706398 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician VR (CVR)
Number of subjects: 79
Study 34706398 — intervention group
Group type: EXPERIMENTAL
Intervention: Trainee VR (TVR)
Number of subjects: 79
Study 34706398 — intervention group
Group type: COMPARATOR
Intervention: Trainee RP (TRP)
Number of subjects: 79
Study 33459249 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 240
Study 33459249 — intervention group
Group type: COMPARATOR
Intervention: Interrupted sutures
Number of subjects: 240
Study 32710498 — intervention group
Group type: EXPERIMENTAL
Intervention: BEACOPP
Number of subjects: 1227
Study 32710498 — intervention group
Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 1227
Study 32122161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 182
Study 32122161 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 182
Study 32122161 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 182
Study 35802960 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-enhanced nurse-facilitated self-care intervention
Number of subjects: 210
Study 35802960 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study 34358271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases with DSM-IV TR Axis-I & II disorders
Number of subjects: 439
Study 34358271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases
Number of subjects: 439
Study 34358271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases with depressive episode
Number of subjects: 439
Study 34358271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases, males aged >= 30 years with alcohol use disorder
Number of subjects: 439
Study 34358271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases, females aged 10-19 years with borderline personality traits
Number of subjects: 439
Study 34358271 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate self-poisoning (DSP) cases, older participants with depressive disorder and alcohol-related disorders
Number of subjects: 439
Study 34358271 — intervention group
Group type: COMPARATOR
Intervention: Controls (age, sex, and residential area matched)
Number of subjects: 439
Study 32548299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Sphericity (SPH) at pretreatment (T0)
Number of subjects: 220
Study 32548299 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor Sphericity (SPH) at early-treatment (T1)
Number of subjects: 220
Study 32548299 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) at T0
Number of subjects: 220
Study 32548299 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) at T1
Number of subjects: 220
Study 32548299 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) for HR-/HER2+ subtype at T0
Number of subjects: 220
Study 32548299 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver Operating Characteristic Curve (AUC) for HR-/HER2+ subtype at T1
Number of subjects: 220
Study 36735054 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg (Prolia, Amgen Inc.) administered at baseline, 6, and 12 months
Number of subjects: 14
Study 36735054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 33452957 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCE Dialyze (370 kcal/day for 30 days)
Number of subjects: 80
Study 33452957 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPRO (370 kcal/day for 30 days)
Number of subjects: 80
Study 33452957 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 80
Study 33452957 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCE Dialyze
Number of subjects: 80
Study 33452957 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPRO
Number of subjects: 80
Study 33452957 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 35096113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (500 mg twice a day)
Number of subjects: 60
Study 35096113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34893880 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 15
Study 34893880 — intervention group
Group type: COMPARATOR
Intervention: Ad lib use
Number of subjects: 15
Study 33694167 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit teaching of the stem conservation rule in derived words
Number of subjects: 90
Study 33694167 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit teaching of the stem conservation rule in derived words
Number of subjects: 90
Study 33694167 — intervention group
Group type: COMPARATOR
Intervention: Unseen control group (no explicit or implicit teaching)
Number of subjects: 90
Study 32893346 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational internal locus of control
Number of subjects: 367
Study 32893346 — intervention group
Group type: EXPERIMENTAL
Intervention: Conflictual communication
Number of subjects: 367
Study 32893346 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 367
Study 32893346 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational climate
Number of subjects: 367
Study 34369681 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electrical acupoint stimulation)
Number of subjects: 49
Study 34369681 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo TEAS)
Number of subjects: 49
Study 32864799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with radiation
Number of subjects: 2
Study 32864799 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab with radiation
Number of subjects: 2
Study 33350726 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 100
Study 33350726 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 100
Study 33632884 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 33
Study 33632884 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 33
Study 33278255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear
Number of subjects: 60
Study 33278255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical headgear and utility arch
Number of subjects: 60
Study 33278255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 60
Study 32819025 — intervention group
Group type: EXPERIMENTAL
Intervention: Sim-Insole with auditory feedback
Number of subjects: 20
Study 32819025 — intervention group
Group type: COMPARATOR
Intervention: Standard bathroom scale (BS) method
Number of subjects: 20
Study 32819025 — intervention group
Group type: COMPARATOR
Intervention: Sim-Insole without feedback
Number of subjects: 20
Study 32799397 — intervention group
Group type: EXPERIMENTAL
Intervention: DrugFactsBox with SMART program
Number of subjects: 286
Study 32799397 — intervention group
Group type: COMPARATOR
Intervention: DrugFactsBox without SMART program
Number of subjects: 286
Study 32799397 — intervention group
Group type: EXPERIMENTAL
Intervention: Other consumer medication information (CMI) with SMART program
Number of subjects: 286
Study 32799397 — intervention group
Group type: COMPARATOR
Intervention: Other CMI without SMART program
Number of subjects: 286
Study 32495663 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose GnRH-a
Number of subjects: 80
Study 32495663 — intervention group
Group type: COMPARATOR
Intervention: Single-dose GnRH-a
Number of subjects: 80
Study 34633758 — intervention group
Group type: EXPERIMENTAL
Intervention: Kami Guibi-tang (KGT)
Number of subjects: 30
Study 34633758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32746864 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine with 20 μg of fentanyl (1 ml)
Number of subjects: 300
Study 32746864 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine with 5 μg of DEX (1 ml)
Number of subjects: 300
Study 32746864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine with saline (1 ml)
Number of subjects: 300
Study 36398589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 36398589 — intervention group
Group type: COMPARATOR
Intervention: Brain Health education (Control)
Number of subjects: 0
Study 32838555 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust-based continuous quality improvement intervention
Number of subjects: 0
Study 32838555 — intervention group
Group type: COMPARATOR
Intervention: Imputation and per protocol approaches
Number of subjects: 0
Study 36454357 — intervention group
Group type: EXPERIMENTAL
Intervention: XP‐endo Finisher
Number of subjects: 92
Study 36454357 — intervention group
Group type: COMPARATOR
Intervention: Control (no XP‐endo Finisher)
Number of subjects: 92
Study 36454357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (XP‐endo Finisher and Control)
Number of subjects: 92
Study 33579766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop system
Number of subjects: 72
Study 33579766 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy
Number of subjects: 72
Study 32357269 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency theta burst stimulation
Number of subjects: 17
Study 32357269 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency theta burst stimulation
Number of subjects: 17
Study 32357269 — intervention group
Group type: COMPARATOR
Intervention: Conventional subthalamic DBS
Number of subjects: 17
Study 36125791 — intervention group
Group type: EXPERIMENTAL
Intervention: Glare (continuous, off‐axis)
Number of subjects: 40
Study 36125791 — intervention group
Group type: COMPARATOR
Intervention: No glare
Number of subjects: 40
Study 36125791 — intervention group
Group type: EXPERIMENTAL
Intervention: Glare and No glare (both conditions)
Number of subjects: 40
Study 34067240 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with Harpagophytum procumbens, Zingiber officinale and Bixa orellana (2 g/day in 6 doses for 4 weeks)
Number of subjects: 28
Study 34067240 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 28
Study 32371830 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP set according to Poeso measurement
Number of subjects: 44
Study 32371830 — intervention group
Group type: COMPARATOR
Intervention: PEEP constantly set at 5 cmH2O (control group)
Number of subjects: 44
Study 34037888 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental Friendship Coaching (PFC)
Number of subjects: 172
Study 34037888 — intervention group
Group type: COMPARATOR
Intervention: Coping with ADHD through Relationships and Education (CARE)
Number of subjects: 172
Study 34021963 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Demodex density (greater than 5 mites/cm2)
Number of subjects: 349
Study 34021963 — intervention group
Group type: EXPERIMENTAL
Intervention: Demodex density
Number of subjects: 349
Study 34021963 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant dermatological disease
Number of subjects: 349
Study 34021963 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent cosmetic use
Number of subjects: 349
Study 33491091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (GL) diet
Number of subjects: 30
Study 33491091 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Load (GL) meal
Number of subjects: 30
Study 33491091 — intervention group
Group type: COMPARATOR
Intervention: High Glycemic Load (GL) meal
Number of subjects: 30
Study 35790450 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry (MTC) juice
Number of subjects: 44
Study 35790450 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry (MTC) capsules
Number of subjects: 44
Study 35790450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 35790450 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry (MTC) supplementation
Number of subjects: 44
Study 36038585 — intervention group
Group type: COMPARATOR
Intervention: Zinc acetate 50 mg × 3 daily
Number of subjects: 40
Study 36038585 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate 50 mg × 3
Number of subjects: 40
Study 36038585 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc acetate 150 mg × 1
Number of subjects: 40
Study 36038585 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate 150 mg × 1
Number of subjects: 40
Study 33037644 — intervention group
Group type: EXPERIMENTAL
Intervention: Education sessions for interns, residents, and clinical pharmacists about appropriate analgesic prescribing.
Number of subjects: 973
Study 35087650 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic oropharyngeal aspiration
Number of subjects: 96
Study 35087650 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing measures (Control)
Number of subjects: 96
Study 33006602 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of diclofenac etalhyaluronate (DF-HA) intra-articularly at weeks 0, 4, and 8
Number of subjects: 176
Study 33006602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 32208038 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000/ferric derisomaltose (IIM)
Number of subjects: 0
Study 32208038 — intervention group
Group type: COMPARATOR
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 0
Study 36216432 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (triggered by Hb ≤100 g/L)
Number of subjects: 742
Study 36216432 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (triggered by Hb ≤70 g/L)
Number of subjects: 742
Study 36216432 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 742
Study 36216432 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 742
Study 34554027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐lock bag (VB group)
Number of subjects: 100
Study 34554027 — intervention group
Group type: COMPARATOR
Intervention: Thermoplastic mask (TM group)
Number of subjects: 100
Study 33962104 — intervention group
Group type: EXPERIMENTAL
Intervention: lncRNAs identified from medaka testis
Number of subjects: 5317
Study 33962104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-regulated target genes predicted from lncRNAs
Number of subjects: 5317
Study 33962104 — intervention group
Group type: EXPERIMENTAL
Intervention: Target genes involved in biological pathways
Number of subjects: 5317
Study 33962104 — intervention group
Group type: EXPERIMENTAL
Intervention: MSTRG.14827.1 lncRNA
Number of subjects: 5317
Study 33445924 — intervention group
Group type: EXPERIMENTAL
Intervention: Hem-o-lok clips
Number of subjects: 120
Study 33445924 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoloop
Number of subjects: 120
Study 33445924 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler
Number of subjects: 120
Study 33445924 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study 33484775 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafibranor 80 mg
Number of subjects: 45
Study 33484775 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafibranor 120 mg
Number of subjects: 45
Study 33484775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 33484775 — intervention group
Group type: EXPERIMENTAL
Intervention: Elafibranor
Number of subjects: 45
Study 34961398 — intervention group
Group type: EXPERIMENTAL
Intervention: Making health care decisions
Number of subjects: 2037
Study 34961398 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicting health care decisions
Number of subjects: 2037
Study 34961398 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social norms
Number of subjects: 2037
Study 34612663 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Bifidobacterium lactis Probio‐M8 powder and Symbicort Turbuhaler)
Number of subjects: 55
Study 34612663 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo and Symbicort Turbuhaler)
Number of subjects: 55
Study 32775408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for Overall Survival (OS)
Number of subjects: 6395
Study 32775408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for Cancer-Specific Survival (CSS)
Number of subjects: 6395
Study 32775408 — intervention group
Group type: COMPARATOR
Intervention: Nomogram vs. histological type in Decision Curve Analysis (DCA)
Number of subjects: 6395
Study 35099597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless tibial components
Number of subjects: 53
Study 35099597 — intervention group
Group type: COMPARATOR
Intervention: Cemented tibial components
Number of subjects: 53
Study 33314326 — intervention group
Group type: COMPARATOR
Intervention: RP3128 (25, 50, 100, 200, and 400 mg single doses; 25, 100, and 400 mg once daily for 7 days)
Number of subjects: 56
Study 33314326 — intervention group
Group type: COMPARATOR
Intervention: RP3128
Number of subjects: 56
Study 35918787 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention for HRQOL
Number of subjects: 331
Study 35918787 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 331
Study 36266713 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic combined intrarenal surgery (ECIRS) in the prone split-leg position
Number of subjects: 66
Study 36266713 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic combined intrarenal surgery (ECIRS) in the Galdakao-modified supine Valdivia (GMSV) position
Number of subjects: 66
Study 34394889 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin pill (given on the basis of conventional treatment)
Number of subjects: 206
Study 34394889 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 206
Study 33172321 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training on a force platform with visual feedback technique
Number of subjects: 30
Study 33172321 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (hot pack therapy, interferential current, myofascial relaxation, cervical dynamic isometric exercises)
Number of subjects: 30
Study 34557087 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole 1,000 mg three times daily for 7 days
Number of subjects: 15
Study 34557087 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily for 7 days
Number of subjects: 15
Study 32371514 — intervention group
Group type: EXPERIMENTAL
Intervention: Farmers' Market Nutrition Coupon Programme (FMNCP)
Number of subjects: 132
Study 32371514 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 132
Study 35988569 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Number of subjects: 316